WHO, partners aim to get Africa 30% of needed doses by Feb

Tuesday, September 14, 2021 | The Associated Press


In this Wednesday, July 28, 2021 file photo, a health worker administers a dose of Janssen COVID-19 vaccine by Johnson & Johnson in the Medina neighborhood in Dakar, Senegal. The World Health Organization and partners said on Tuesday, Sept. 14 they hope to provide Africa with about 30% of the COVID-19 vaccines they need by February, badly missing the 60% vaccination coverage goal that African leaders had once hoped for by the end of this year. (AP Photo/Leo Correa, file)

GENEVA (AP) — The World Health Organization and its partners said they hope to provide Africa with about 30% of the COVID-19 vaccines the continent needs by February, badly missing the 60% vaccination coverage goal that African leaders had once hoped for this year.

At a press briefing Tuesday, WHO director-general Tedros Adhanom Ghebreyesus called the massive disparity in vaccination rates between rich and poor countries a “solvable problem” and called again for pharmaceutical companies to prioritize the U.N.-backed initiative known as COVAX, which is designed to share vaccines globally.

But drugmakers — including Pfizer-BioNTech and Moderna — have shown no indications they are eager to switch their current tactics, which involve appealing to rich countries and their regulators to authorize booster shots.

Tedros called last week for a “moratorium” on the use of boosters in healthy populations until the end of the year. Countries including Israel, France and Germany have already started dispensing third doses to certain people; the U.K. announced plans on Tuesday to offer boosters to anyone over 50 as well as younger people who might be more vulnerable to COVID-19.

In the U.S., the FDA is going to publicly debate the topic of boosters this week. In an opinion piece this week, two top FDA officials and senior WHO scientists wrote in the Lancet that the average person doesn't need a booster shot.

To date, fewer than 4% of Africans have been fully immunized and most of the 5.7 billion vaccine doses administered around the world have been given in just 10 rich countries.

COVAX has missed nearly all its targets and has now resorted to begging rich countries to share their vaccine doses.

Dr. Seth Berkley, CEO of vaccines alliance Gavi, said COVAX expects to have 1.4 billion doses ready for delivery by the end of this year, about one quarter fewer than its original goal.

Afreximbank President Benedict Oramah warned that booster shots in Africa would require $500 million to $600 million more “on the conservative side,” and if the cost of logistics is included, that would mean $1 billion a year.

Strive Masiyiwa, the African Union's envoy for COVID-19 vaccines, also called for export restrictions and intellectual property rights to be lifted to allow vaccine production within Africa.

In June, WHO and its partners launched a hub in South Africa intended to transfer technology needed to make the vaccines produced by Pfizer-BioNTech and Moderna, but none of those companies have yet agreed to share their vaccine recipes.

“It’s not an unreasonable call, because our neighbors in the U.S. supported these companies to produce some of these vaccines,” Masiyiwa said. “Now let this miracle to be available to all mankind.”

___

Follow all AP stories about the coronavirus pandemic at https://apnews.com/hub/coronavirus-pandemic.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.7$44.35+0.9%3.52%19.03Hold$43.33
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.